1. Home
  2. GLU vs CUE Comparison

GLU vs CUE Comparison

Compare GLU & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Global Utility of Beneficial Ownership

GLU

Gabelli Global Utility of Beneficial Ownership

N/A

Current Price

$19.33

Market Cap

116.1M

Sector

Finance

ML Signal

N/A

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$32.06

Market Cap

127.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLU
CUE
Founded
2004
2014
Country
United States
United States
Employees
N/A
29
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.1M
127.8M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
GLU
CUE
Price
$19.33
$32.06
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$120.00
AVG Volume (30 Days)
6.1K
170.5K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
8.60%
N/A
EPS Growth
N/A
61.11
EPS
0.62
N/A
Revenue
N/A
$27,466,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$31.19
N/A
Revenue Growth
N/A
195.75
52 Week Low
$17.62
$0.17
52 Week High
$21.69
$45.50

Technical Indicators

Market Signals
Indicator
GLU
CUE
Relative Strength Index (RSI) 55.39 57.57
Support Level $19.32 $24.68
Resistance Level $20.17 $33.73
Average True Range (ATR) 0.27 3.25
MACD 0.02 0.12
Stochastic Oscillator 75.87 75.81

Price Performance

Historical Comparison
GLU
CUE

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Share on Social Networks: